Background: Polycystic ovary syndrome (PCOS) is a cardiometabolic disorder whose features include dyslipidemia, increased oxidative stress (OS, oxy) and chronic inflammation. The aim of this study was to investigate the ability of a summary score for dyslipidemia, OS and inflammation (the DOI score) to discriminate PCOS patients from healthy individuals and to evaluate the effect of obesity on individual scores and the DOI score in patients.
Methods: Lipid status parameters, OS status parameters (advanced oxidation protein products; total oxidative status; prooxidant-antioxidant balance; malondialdehyde; total protein sulphydryl groups and paraoxonase 1 activity) and CRP were measured in 114 patients and 50 controls using standardised assays. The DOI score was calculated as the sum of dyslipidemia, oxy and inflammation scores, determined as Z-score values for every subject in relation to the controls.
Results: PCOS patients had significantly higher oxy-score compared to controls (P<0.001). In addition, the DOI score was significantly higher in PCOS patients (P<0.001) as the dyslipidemia (P<0.05) and inflammatory scores (P<0.001) were greater. According to ROC analysis, the oxy-score showed better diagnostic accuracy in discriminating PCOS patients compared to the DOI score (AUC>0.9, P<0.01). Furthermore, obesity affected the risk scores in patients, especially the DOI score (significantly higher DOI scores in such patients, P<0.001).
Conclusion: PCOS patients had greater dyslipidemia, chronic inflammation and OS compared to controls and could be segregated using all four scores. Our data suggest that weight gain could be the common factor responsible for induction and propagation of dyslipidemia, OS and inflammation in PCOS patients.
1. Collinson P. Laboratory medicine is faced with the evolution of medical practice. J Med Biochem 2017; 36: 211–5.
2. Macut D, Bačević M, Božić-Antić I, Bjekić-Macut J, Čivčić M, Erceg S et al. Predictors of subclinical cardiovascular disease in women with PCOS: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015; 2015: 1–9.
3. Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013; 40: 51–63.
4. Repaci A, Gambineri A, Pasquali R. The role of lowgrade inflammation in the polycystic ovary syndrome. Molec Cell End 2011; 335: 30–41.
5. Macut D, Micić D, Cvijović G, Šumarac M, Kendereški A, Zorić S et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001; 14: 1353–9.
6. Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to control. Clin Endocrinol 2001; 54: 455–62.
7. Perovic Bragojevic I, Eror T, Pelivanovic J, Jelic S, Kotur- Stevuljevic J, Ignjatovic S. Women with polycystic ovary syndrome and risk of cardiovascular disease. J Med Biochem 2017; 36: 259–69.
8. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 336–40.
9. Papalou O, Victor VM, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr Pharm Des 2016; 22: 2709–22.
10. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human Reproduction Update 2013; 19: 268–88.
11. Kaya C, Pabuccu R, Berker B, Satiroglu H. Plasma interleukin- 18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertil Steril 2010; 93: 1200–7.
12. Lambert EA, Teede H, Sari CI, Jona E, Shorakae S, Woodington K et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clin Endocrinol 2015; 83: 812–9.
13. Macut D, Simić T, Lissounov A, Plješa-Ercegovac M, Božić I, Djukić T et al. Insulin resistance in non-obese women with polycystic ovary syndrome: relation to by-products of oxidative stress. Exp Clin Endocrinol Diabetes 2011; 119: 451–5.
14. The Rotterdam ESHRE/ASRM-Sponsored PCOS Con sensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2003; 19: 41–7.
15. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990; 36: 15–9.
16. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49: 1304–13.
17. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38: 1103–11.
18. O. Erel, A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277–85.
19. Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007, 40: 248–54.
20. Girotti MJ, Khan N, McLellan BA. Early measurement of systemic lipid peroxidation products in plasmaof major blunt trauma patients. J Trauma, 1991, 31: 32–5.
22. Misra HP, Fridovich I. Chemistry and metabolism of substances of low molecular weight: the role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170–5.
23. Kotur-Stevuljević J, Bogavac-Stanojević N, Jelić-Ivanović Z, Stefanović A, Gojković T, Joksić J et al. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis 2015; 241: 192–8.
24. Veglia F, Cighetti G, De Franceschi M, Zingaro L, Boccotti L, Tremoli E et al. Age- and gender-related oxidative status determined in healthy subjects by means of OXY-SCORE, a potential new comprehensive index. Bio-markers 2006; 11: 562–73.
25. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: a result of a case-control study. J Clin Epidemiol 1998; 51: 415–22.
26. Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women. Metabolism 2009; 58: 714–21.
27. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol 1994; 41: 463–71.
28. Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. PCOS is associated with atherogenic changes in lipoprotein particle number and size independent of body weight. Clin Endocrinol 2011; 75: 76–82.
29. Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH et al. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod 2013; 28: 1354–60.
30. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and metaanalisys. Fertil Steril 2011; 95: 1073–9.
31. Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol 2013; 56: 137–42.
32. Kotur-Stevuljević J, Memon L, Stefanović A, Spasić S, Spasojević-Kalimanovska V, Bogavac-Stanojević N et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 2007; 40: 181–7.
33. Kaplan M, Ates I, Yüksel M, Ozderin Ozin Y, Yener Akpinar M, Topcuoglu C, Kayaçetin E. The role of oxidative stress in the etiopathogenesis of gluten-sensitive enteropathy disease. J Med Biochem 2017: 36: 243–50.
34. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011; 95: 1048–58.
35. Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patiens with polycystic ovary syndrome. Fertil Steril 2009; 92: 1372–7.
36. Heshmati N, Shahgheibi S, Nikkhoo B, Amini S, Abdi M. Association of prooxidant-antioxidant balance with clinical and laboratory parameters and its relation to different drug regimens in polycystic ovary syndrome women with normal BMI. Indian J Clin Biochem 2017; 32: 315–22.
37. Artimani T, Karimi J, Mehdizadeh M, Yavangi M, Khanlarzadeh E, Ghorbani M et al. Evaluation of pro-oxidantantioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2017; 4: 1–5.
38. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006; 21: 104–8.
39. Baskol G, Aygen E, Erdem F, Caniklioglu A, Narin F, Sahin Y, Kaya T. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstetricia Gynecol Scandinavica 2012; 91: 326–30.
40. Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril 2014; 102: 1167–74.
41. Marseglia L, D Angelo G, Manti S, Aversa S, Arrigo T, Reiter RJ, Gitto E. Oxidative stress in obesity: a critical component in human disease. Int J Mol Sci 2015; 16: 378–400.
42. Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag 2007; 3: 69–73.